ArticleJournal of gastroenterology2015
A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA(+)-M2BP), for assessing liver fibrosis.
Article in Journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 2 syntheses or guidelines pooled it, 179 citations in OpenAlex.
- Mac-2 binding protein glycosylation isomer as a novel serum biomarker for recurrence in hepatocellular carcinoma.World journal of gastroenterology · 2026Pooled it
- Wisteria floribunda agglutinin-positive Mac-2-binding protein as a diagnostic biomarker in liver cirrhosis: an updated meta-analysis.Scientific reports · 2020Pooled it
- Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD.Hepatology communications · 2022Trial
- Association of M2BPGi with Subclinical Atherosclerosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.Metabolites · 2026Article
- CLEIA-based type IV collagen 7S for second-step assessment of MRE-defined clinically significant fibrosis in MASLD with indeterminate FIB-4.Scientific reports · 2026Article
- Evaluation methods of hepatic steatosis: From conventional techniques to emerging biomarkers.World journal of hepatology · 2026Review
- Sequential Fibrosis-4 Index and Mac-2 Binding Protein Glycosylation Isomer Combination Improve Detection of Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Multicenter Study.Gastro hep advances · 2026Article
- Plasma Fibulin-5 as a Novel Marker for Advanced Fibrosis in Chronic Hepatitis C.Gastro hep advances · 2026Article
- Follow-up of jaundice-free biliary atresia survivors using M2BPGi and APRI in a local hospital.World journal of pediatric surgery · 2026Article
- Estimation the Change in Liver Fibrosis Stage with Serial Measurement of Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein in Metabolic Dysfunction-Associated Steatotic Liver Disease Patients.International journal of molecular sciences · 2025Article
- Assessing the role of Mac-2 binding protein glycosylation isomer in the management of patients with chronic hepatitis B.World journal of hepatology · 2025Article
- Fibrotic liver injury in biliary atresia: long-term implications.World journal of pediatric surgery · 2025Review
- Mac-2 binding protein glycosylation isomer as a novel predictor of early recurrence after resection for hepatocellular carcinoma.Surgery today · 2025Article
- Role of Essential Oils and Antioxidants in the Treatment of Fibrosis.Current drug research reviews · 2025Review
- Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation.Journal of gastroenterology · 2024Article
- Article
- Serum biomarkers for liver fibrosis assessment.Advances in laboratory medicine · 2024Review
- New chemiluminescent enzyme immunoassay for quantitative measurement of Mac-2 binding protein glycosylation isomer in chronic liver disease.Journal of gastroenterology · 2023Article
- Current status of preoperative risk assessment for posthepatectomy liver failure in patients with hepatocellular carcinoma.Annals of gastroenterological surgery · 2023Review
- The Natural History and Management of Hepatic Hemangioma.Journal of clinical medicine · 2023Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecently, a novel marker, hyperglycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA(+)-M2BP), was developed for liver fibrosis using the glycan "sugar chain"-based immunoassay; however, the feasibility of WFA(+)-M2BP for assessing liver fibrosis has not been proven with clinical samples of hepatitis.
methodsSerum WFA(+)-M2BP values were evaluated in 200 patients with chronic liver disease who underwent histological examination of liver fibrosis. The diagnostic accuracy of WFA(+)-M2BP values was compared with various fibrosis markers, such as ultrasound based-virtual touch tissue quantification (VTTQ), magnetic resonance imaging based-liver-to-major psoas muscle intensity ratio (LMR), and serum markers, including hyaluronic acid, type 4 collagen, and aspartate transaminase to platelet ratio index (APRI).
resultsSerum WFA(+)-M2BP levels in patients with fibrosis grades F0, F1, F2, F3, and F4 had cutoff indices 1.62, 1.82, 3.02, 3.32, and 3.67, respectively, and there were significant differences between fibrosis stages F1 and F2, and between F2 and F3 (P < 0.01). The area under the receiver operating characteristic curves for the diagnosis of fibrosis (F ≥ 3) using serum WFA(+)-M2BP values (0.812) was almost comparable to that using VTTQ examination (0.814), but was superior to the other surrogate markers, including LMR index (0.766), APRI (0.694), hyaluronic acid (0.683), and type 4 collagen (0.625) (P < 0.01 each).
conclusionsSerum WFA(+)-M2BP values based on a glycan-based immunoassay is an accurate, reliable, and reproducible method for the assessment of liver fibrosis. This approach could be clinically feasible for evaluation of beneficial therapy through the quantification of liver fibrosis in hepatitis patients if this measurement application is commercially realized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.